Effect of Vedolizumab Treatment on Extraintestinal Manifestations in Patients with Crohn’s Disease: A Gemini 2 Post hoc Analysis

Feagan, Brian G.; Sandborn, William J.; Colombel, Jean Fréd́eric; O’Byrne, Sharon; Khalid, Javaria Mona; Brayshaw, Nigel; Geransar, Parnia; Rubin, David T.

doi:10.1016/s0016-5085(17)32137-6

Cited by 4 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We belief that vedolizumab will more likely have a beneficial, rather than a paradoxical, effect in patients with concomitant IBD and SpA. Several recent clinical data support this expectation [111][112][113] A c c e p t e d M a n u s c r i p t Table 2: Classification of IBD-related arthritis according to ECCO consensus (2016) 3 . A c c e p t e d M a n u s c r i p t Table 3: Diagnostic clues for referral of the IBD patient to the rheumatologist and for referral of the SpA patient to the gastroenterologist 4,5 .…”

Section: A N U S C R I P Tmentioning

confidence: 98%

Management of patients with inflammatory bowel disease and spondyloarthritis

Pouillon

Bossuyt

Vanderstukken

et al. 2017

Expert Review of Clinical Pharmacology

View full text Add to dashboard Cite

More than half of the patients with inflammatory bowel disease (IBD) experience at least one extra-intestinal manifestation (EIM). The most common EIM in patients with IBD is spondyloarthritis (SpA). Microscopic intestinal inflammation is documented in almost 50% of the patients with SpA. Areas covered: We give an overview of the classification, the epidemiology and the diagnosis of IBD and SpA. The treatment goals, the pharmacologic management options and the available treatment guidelines in IBD patients with SpA are discussed. Expert commentary: The coexistence of IBD and SpA generates challenges and opportunities for both the gastroenterologist and the rheumatologist. The potential of drugs with a gut-specific mode of action in the treatment of IBD-related arthritis warrants further exploration.

show abstract

Section: A N U S C R I P Tmentioning

confidence: 98%

Management of patients with inflammatory bowel disease and spondyloarthritis

Pouillon

Bossuyt

Vanderstukken

et al. 2017

Expert Review of Clinical Pharmacology

View full text Add to dashboard Cite

show abstract

Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease

et al. 2018

Self Cite

View full text Add to dashboard Cite

BackgroundApproximately 15–20% of ulcerative colitis patients and 20–40% of those with Crohn’s disease experience extraintestinal manifestations (EIMs) of their inflammatory bowel disease (IBD). Clinicians who treat IBD must manage EIMs affecting multiple organs that variably correlate with intestinal disease activity. Vedolizumab is a monoclonal antibody for the treatment of IBD with a gut-selective mechanism of action.AimsThis report evaluates whether vedolizumab is an effective treatment of EIMs, given its gut-specific mechanism of action.MethodsWe report 8 case studies of patients with various EIMs, including pyoderma gangrenosum, peripheral arthralgia/arthritis, axial arthropathies, erythema nodosum, and uveitis, who received vedolizumab therapy.ResultsVedolizumab therapy was effective for pyoderma gangrenosum in ulcerative colitis, uveitis, erythema nodosum, polyarticular arthropathy, and ankylosing spondylitis/sacroiliitis but did not provide sustained benefit for the treatment of pyoderma gangrenosum in a patient with Crohn’s disease.ConclusionsThese cases demonstrate the potential of vedolizumab as a treatment of EIMs in patients with IBD.

show abstract